TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Down 56.6% in June

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the target of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totalling 24,900 shares, a decrease of 56.6% from the May 31st total of 57,400 shares. Based on an average trading volume of 2,310,000 shares, the short-interest ratio is currently 0.0 days.

TC Biopharm Trading Down 1.2 %

Shares of TC Biopharm stock traded down $0.01 on Friday, reaching $0.82. 79,738 shares of the company’s stock were exchanged, compared to its average volume of 2,843,157. TC Biopharm has a 52 week low of $0.72 and a 52 week high of $19.60. The firm’s 50-day moving average is $1.16 and its two-hundred day moving average is $1.58. The company has a debt-to-equity ratio of 1.31, a current ratio of 0.88 and a quick ratio of 0.88.

TC Biopharm (NASDAQ:TCBP) last issued its earnings results on Wednesday, May 15th. The company reported ($2.80) earnings per share for the quarter.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.